Clinical trials of disease-modifying agents in pediatric MS: Opportunities, challenges, and recommendations from the IPMSSG

IPMSSG

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: The impetus for this consensus discussion was to recommend clinical trial designs that can deliver high-quality data for effective therapies for pediatric patients, in a reasonable timeframe, with a key focus on short- and long-term safety. METHODS: The International Pediatric Multiple Sclerosis Study Group convened a meeting of experts to review the advances in the understanding of pediatric-onset multiple sclerosis (MS) and the advent of clinical trials for this population. RESULTS: In the last few years, convincing evidence has emerged that the biological processes involved in MS are largely shared across the age span. As such, treatments proven efficacious for the care of adults with MS have a biological rationale for use in pediatric MS given the relapsing-remitting course at onset and high relapse frequency. There are also ethical considerations on conducting clinical trials in this age group including the use of placebo owing to highly active disease. It is imperative to reconsider study design and implementation based on what information is needed. Are studies needed for efficacy or should safety be the primary goal? Further, there have been major recruitment challenges in recently completed and ongoing pediatric MS trials. Phase 3 trials for every newly approved therapy for adult MS in the pediatric MS population are simply not feasible. CONCLUSIONS: A primary goal is to ensure high-quality evidence-based treatment for children and adolescents with MS, which will improve our understanding of the safety of these agents and remove regulatory or insurance-based limitations in access to treatment.

Original languageEnglish
Pages (from-to)e2538-e2549
JournalNeurology
Volume92
Issue number22
DOIs
Publication statusPublished - May 28 2019

Fingerprint

Multiple Sclerosis
Clinical Trials
Pediatrics
Safety
Biological Phenomena
Therapeutics
Relapsing-Remitting Multiple Sclerosis
Insurance
Population
Age Groups
Placebos
Recurrence

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Clinical trials of disease-modifying agents in pediatric MS : Opportunities, challenges, and recommendations from the IPMSSG. / IPMSSG.

In: Neurology, Vol. 92, No. 22, 28.05.2019, p. e2538-e2549.

Research output: Contribution to journalArticle

@article{2d9e6a8394674f119d66fb6be8d7ad6c,
title = "Clinical trials of disease-modifying agents in pediatric MS: Opportunities, challenges, and recommendations from the IPMSSG",
abstract = "OBJECTIVE: The impetus for this consensus discussion was to recommend clinical trial designs that can deliver high-quality data for effective therapies for pediatric patients, in a reasonable timeframe, with a key focus on short- and long-term safety. METHODS: The International Pediatric Multiple Sclerosis Study Group convened a meeting of experts to review the advances in the understanding of pediatric-onset multiple sclerosis (MS) and the advent of clinical trials for this population. RESULTS: In the last few years, convincing evidence has emerged that the biological processes involved in MS are largely shared across the age span. As such, treatments proven efficacious for the care of adults with MS have a biological rationale for use in pediatric MS given the relapsing-remitting course at onset and high relapse frequency. There are also ethical considerations on conducting clinical trials in this age group including the use of placebo owing to highly active disease. It is imperative to reconsider study design and implementation based on what information is needed. Are studies needed for efficacy or should safety be the primary goal? Further, there have been major recruitment challenges in recently completed and ongoing pediatric MS trials. Phase 3 trials for every newly approved therapy for adult MS in the pediatric MS population are simply not feasible. CONCLUSIONS: A primary goal is to ensure high-quality evidence-based treatment for children and adolescents with MS, which will improve our understanding of the safety of these agents and remove regulatory or insurance-based limitations in access to treatment.",
author = "IPMSSG and Emmanuelle Waubant and Brenda Banwell and Evangeline Wassmer and Sormani, {Maria Pia} and Amato, {Maria Pia} and Rogier Hintzen and Lauren Krupp and Kevin Rost{\'a}sy and Silvia Tenembaum and Tanuja Chitnis",
year = "2019",
month = "5",
day = "28",
doi = "10.1212/WNL.0000000000007572",
language = "English",
volume = "92",
pages = "e2538--e2549",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "22",

}

TY - JOUR

T1 - Clinical trials of disease-modifying agents in pediatric MS

T2 - Opportunities, challenges, and recommendations from the IPMSSG

AU - IPMSSG

AU - Waubant, Emmanuelle

AU - Banwell, Brenda

AU - Wassmer, Evangeline

AU - Sormani, Maria Pia

AU - Amato, Maria Pia

AU - Hintzen, Rogier

AU - Krupp, Lauren

AU - Rostásy, Kevin

AU - Tenembaum, Silvia

AU - Chitnis, Tanuja

PY - 2019/5/28

Y1 - 2019/5/28

N2 - OBJECTIVE: The impetus for this consensus discussion was to recommend clinical trial designs that can deliver high-quality data for effective therapies for pediatric patients, in a reasonable timeframe, with a key focus on short- and long-term safety. METHODS: The International Pediatric Multiple Sclerosis Study Group convened a meeting of experts to review the advances in the understanding of pediatric-onset multiple sclerosis (MS) and the advent of clinical trials for this population. RESULTS: In the last few years, convincing evidence has emerged that the biological processes involved in MS are largely shared across the age span. As such, treatments proven efficacious for the care of adults with MS have a biological rationale for use in pediatric MS given the relapsing-remitting course at onset and high relapse frequency. There are also ethical considerations on conducting clinical trials in this age group including the use of placebo owing to highly active disease. It is imperative to reconsider study design and implementation based on what information is needed. Are studies needed for efficacy or should safety be the primary goal? Further, there have been major recruitment challenges in recently completed and ongoing pediatric MS trials. Phase 3 trials for every newly approved therapy for adult MS in the pediatric MS population are simply not feasible. CONCLUSIONS: A primary goal is to ensure high-quality evidence-based treatment for children and adolescents with MS, which will improve our understanding of the safety of these agents and remove regulatory or insurance-based limitations in access to treatment.

AB - OBJECTIVE: The impetus for this consensus discussion was to recommend clinical trial designs that can deliver high-quality data for effective therapies for pediatric patients, in a reasonable timeframe, with a key focus on short- and long-term safety. METHODS: The International Pediatric Multiple Sclerosis Study Group convened a meeting of experts to review the advances in the understanding of pediatric-onset multiple sclerosis (MS) and the advent of clinical trials for this population. RESULTS: In the last few years, convincing evidence has emerged that the biological processes involved in MS are largely shared across the age span. As such, treatments proven efficacious for the care of adults with MS have a biological rationale for use in pediatric MS given the relapsing-remitting course at onset and high relapse frequency. There are also ethical considerations on conducting clinical trials in this age group including the use of placebo owing to highly active disease. It is imperative to reconsider study design and implementation based on what information is needed. Are studies needed for efficacy or should safety be the primary goal? Further, there have been major recruitment challenges in recently completed and ongoing pediatric MS trials. Phase 3 trials for every newly approved therapy for adult MS in the pediatric MS population are simply not feasible. CONCLUSIONS: A primary goal is to ensure high-quality evidence-based treatment for children and adolescents with MS, which will improve our understanding of the safety of these agents and remove regulatory or insurance-based limitations in access to treatment.

UR - http://www.scopus.com/inward/record.url?scp=85066967271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066967271&partnerID=8YFLogxK

U2 - 10.1212/WNL.0000000000007572

DO - 10.1212/WNL.0000000000007572

M3 - Article

C2 - 31043474

AN - SCOPUS:85066967271

VL - 92

SP - e2538-e2549

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 22

ER -